TUSTIN, Calif., Aug. 15 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL Inc. (Amex: ADL), a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin China, announced today its chief executive officer Gary Dreher and chief financial officer Akio Ariura will host a teleconference to discuss the Company's second quarter 2008 financial results. The call is scheduled for Tuesday, August 19, 2008 at 1:45 p.m. Pacific Standard Time (4:45 p.m. Eastern Time).
Existing or potential investors who would like to submit questions prior to the call can do so by emailing Kristine Szarkowitz at firstname.lastname@example.org.
To access the live call, please dial (877) 360-1705 in the U.S. or (706) 902-3245 outside the U.S. and reference Conference ID# 60855707 five minutes before the call begins. The conference call script will also be available on the Investor section of the AMDL web site located at http://www.amdl.com. Click on "Investor Relations" then "Recent News" to access the Company's earnings release which was issued today, August 15, 2008, and all other accompanying financial and operating information.
AMDL Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer
market in the world -- China. AMDL, through its Jade subsidiaries,
currently holds licenses for 133 products that are manufactured as large
volume injection fluids, tablets and other related products. It currently
manufactures over 20 key generic, over-the-counter and supplemental
pharmaceutical products under certified Chinese Good Manufacturing Practice
(M) (206) 310-5323
Copyright©2008 PR Newswire.
All rights reserved